Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas Moves For Ouster Of CV Board That Rejected Hostile Bid

This article was originally published in PharmAsia News

Executive Summary

The next time shareholders of U.S.-based CV Therapeutics meet, Astellas Pharma plans to move to oust four of CV's directors. No date has been set for that meeting to consider an Astellas offer to buy the firm that the directors rejected. Astellas said it would follow the ouster with a proposal to name two of the replacement directors. Astellas launched a hostile bid for the company in February. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts